Esperion Therapeutics Inc. (ESPR) has initiated a global phase III long-term safety and tolerability study of Bempedoic acid (ETC-1002) in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.
Forex – financial instrument.Forex news
Esperion Therapeutics Inc. (ESPR) has initiated a global phase III long-term safety and tolerability study of Bempedoic acid (ETC-1002) in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.